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Abstract: Scant attention has been paid to the potential role of gonadotropins in bone tissue 
homeostasis. The focus on estrogen and estrogen replacement therapy for osteoporosis as far 
back as the 1940’s may account for the paucity of gonadotropin studies in bone biology. It is 
conceivable that prevailing dogma may have subconsciously steered us away from addressing 
whether gonadotropins have a place in skeletal physiology. However an examination of bone 
tissue catabolism in ovariectomized (OVX) and luteinizing hormone-releasing hormone (LHRH) 
agonist (Zoladex®)-treated rats generated some interesting and conﬂ  icting data; Zoladex-treated 
rats, unlike the OVX group, failed to exhibit increased bone collagen catabolism despite clear 
evidence for estrogen deﬁ  ciency. The ﬁ  ndings, although controversial, supported the possibility 
that elevated gonadotropins in the OVX model were in some way accountable for increased bone 
catabolism. In response to these initial ﬁ  ndings further studies were performed to determine 
if altered LH status may in some way impact on the skeleton To this end an investigation of 
bone mass and histomorphometry were conducted in LH receptor nullizygous mice and human 
chorionic gonadotropin (hCG) overexpressing mice. There were clear phenotypic differences; 
the LH receptor knockout mice displayed reduced bone mass whereas the hCG overexpressing 
animals had stark increases in bone mass. Much more recently the team of the Mount Sinai Bone 
Program have made a signiﬁ  cant discovery that bone-resorbing osteoclasts express receptors for 
follicle-stimulating hormone (FSH) and that mice nullizygous for FSH receptor are resistant to 
bone loss despite severe estrogen deﬁ  ciency. Details of these fascinating models will be presented 
together with additional ﬁ  ndings that give credence for exploring gonadotropin action on the 
skeleton as we enter the twilight of this Decade of the Bone and Joint.
Keywords: gonadotropins, bone, osteoblasts, osteoclasts, follicle-stimulating hormone, 
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Estrogen’s claim on bone: an historical perspective
In 1941 Fuller Albright and colleagues were the ﬁ  rst to communicate the association 
of osteoporosis (OP) with the menopause. At the time this important revelation was 
made it was generally accepted that the menopause was associated with ovarian failure 
and that estrogen levels declined with the menopause. Since ovarian failure seemed 
synonymous with increased bone loss it was postulated, as early as the 1940’s, that 
replacement estrogen might prevent OP. Certainly in the past two decades, estrogen, 
or hormone replacement therapy (HRT), has been an established prophylaxis for OP 
because it has successfully reduced the extent of bone loss and/or preserved bone 
mass postmenopause (Lindsay 2004; Stevenson 2005). Although it is generally agreed 
that estrogen plays a role in skeletal homeostasis the precise mechanism by which it 
exerts its sparing effect on bone is still not fully understood. To this end a concerted 
global effort has ensued to identify how estrogen contributes to bone metabolism and 
to ascertain if the effects of this steroid hormone are direct or otherwise.International Journal of General Medicine 2008:1 52
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For a considerable time the effects of estrogen on bone 
were thought to be indirect since receptors for estrogen had 
not been isolated from bone tissue. The identiﬁ  cation of 
estrogen receptors in human primary osteoblasts and osteo-
blast-like osteosarcoma cells twenty years ago provided the 
ﬁ  rst indications that a direct effect of estrogen upon bone 
tissue might be involved (Eriksen et al 1988; Komm et al 
1988). Gideon Rodan (1991) proposed that estrogen might 
exert an anabolic action in bone either directly or via the 
generation of local growth factors. Early evidence in support 
of an anabolic action of estrogen in bone came from studies 
using rat osteoblasts (Ernst et al 1989; Gray 1989) in which 
type I collagen mRNA expression increased in response 
to estrogen. However estrogen administration to rats does 
not stimulate bone formation (Westerlind et al 1993). Also, 
research conducted in Rigg’s group found no direct effect 
of estrogen on human osteoblast growth and maturation 
(Keeting et al 1991). Similarly estrogen was without effect 
on type I collagen protein synthesis in human fetal (Robinson 
et al 1997) and adult (Mahonen et al 1998) osteoblasts. 
Although attractive, the possibility that estrogen might elicit 
a direct anabolic action in mammalian bone is certainly not 
compelling; estrogen actually inhibits pre-osteoblast prolif-
eration and decreases osteoblast activity (Turner et al 1994) 
and only modest increases in bone mass have been obtained 
for mice treated with suprapharmacological doses of the 
steroid (Samuels et al 1999). Furthermore a dose of 1500 μg 
estrogen/kg murine body weight was unable to induce endo-
cortical bone formation (Bain et al 1993). Given that 5 μg 
estrogen/kg is sufﬁ  cient to saturate the estrogen receptor 
ligand-binding sites it is highly unlikely that the effect of 
estrogen on any bone formation is via a “conventional path-
way” (Turner 1999). Turner comments that the increased 
bone mass (more speciﬁ  cally, osteosclerosis) reported by 
Samuels and colleagues (1999) is attributed to bone marrow 
toxicity due to the very high circulating estrogen titre. Sufﬁ  ce 
it to say estrogen does not appear to be a particularly potent 
factor in the regulation of bone mass; mice nullizygous for 
either estrogen receptor alpha or beta have normal bone 
mass, furthermore only modest osteopenia is observed in 
mice lacking both receptors (Lindberg et al 2001; McCauley 
et al 2002; Windahl et al 2002).
One other possible inﬂ  uence of estrogen on the skeleton is 
to inhibit the process of bone resorption by osteoclasts. With 
over half a century of basic and clinical research conducted 
after Albright and colleagues made the important connec-
tion between estrogen deﬁ  ciency and OP, Paciﬁ  ci (1998, 
2008) distilled the biological basis of postmenopausal OP 
down to increased bone-resorbing cytokine production. 
The miscreants responsible are chieﬂ  y interleukin-1 (IL-1) 
and tumor necrosis factor-alpha (TNF-α) and their sig-
niﬁ  cance to the pathogenesis of postmenopausal OP will 
become clearer in due course. Most recently Nakamura and 
colleagues (2007) have provided evidence that estrogen 
withdrawal may prolong the life span of osteoclasts which 
in turn might be to the detriment of bone during periods of 
prolonged estrogen deﬁ  ciency. In light of the proven efﬁ  cacy 
of HRT in preserving bone mass postmenopause it is likely 
that estrogen dampens the process of bone resorption rather 
than promoting matrix synthesis.
Menopausal endocrinology is not a simple case of 
estrogen decline. At the time of Albright’s publication in 
1941, far less was known about menopausal endocrinology. 
Although extragonadal factors (primarily from the pituitary) 
were believed to inﬂ  uence gonadal function Herbert McLean 
Evans and colleagues only coined the terms follicle-
stimulating hormone (FSH) and luteinizing hormone (LH) 
four years prior to Albright’s publication (Medvei 1982). 
Furthermore the association between LH/FSH and estrogen 
within the ovarian – pituitary axis was not understood and 
this continued for many years to come. Indeed the dynamic 
link between estrogen and gonadotropins even escaped 
Pincus and Kirsch in 1965 (Medvei 1982). It is widely rec-
ognized that even modest estrogen withdrawal culminates in 
a corresponding rise in both LH and FSH from the anterior 
pituitary. It is particularly noteworthy why investigations into 
LH/FSH on bone metabolism have not, until quite recently, 
been considered despite the inverse and inextricable link 
between circulating estrogen and LH/FSH. It is a genuine 
possibility that raised gonadotropin levels might participate 
in bone resorption and contribute to the pathogenesis of 
postmenopausal OP. A description of how they came to be 
identiﬁ  ed in the context of bone biology and how they might 
impact upon the skeleton are presented below.
Zoladex versus ovariectomy 
in the rat; early indications 
for a role of gonadotropins 
in stimulating bone loss
The biochemical composition and metabolism of bone collagen 
in OP formed the PhD thesis of the author. Part of the PhD 
studies involved the application of the ovariectomized (OVX) 
rat model, a widely used and accepted experimental tool to 
study bone in response to estrogen withdrawal (Saville 1969; 
McOsker and Li 1991; Wronski and Yen 1991). In addition to International Journal of General Medicine 2008:1 53
Gonadotropins and the skeleton
the OVX model, I was keen to explore alternatives to OVX, 
primarily from a welfare point of view. One particularly attrac-
tive alternative to OVX was the application of a depot formu-
lation of the luteinizing hormone-releasing hormone (LHRH) 
agonist goserelin (Zoladex) that had been shown to last at least 
one month (Ward et al 1989). Although the LHRH agonist 
buserelin had been used previously in rats (Goulding and Gold 
1989), this required daily injections and therefore constant 
animal handling, which was something I wanted to avoid.
Total hydroxyproline (Hypro) excretion relative 
to creatinine clearance was used to monitor collagen 
catabolism in the OVX and LHRH models on a weekly 
basis. As expected Hypro excretion rose markedly within 
the ﬁ  rst week of OVX and remained elevated for up to 
3 weeks after which it steadily fell to control levels by the 
sixth week. In marked contrast Zoladex administration led 
to reduced Hypro excretion which returned to control levels 
after one month. A second depot likewise resulted in a 
signiﬁ  cant reduction in Hypro excretion, the levels once again 
rising to controls by week 8. A clear polarization in Hypro 
excretion was evident; OVX was producing the expected 
rise in collagen catabolism whereas estrogen deﬁ  ciency 
triggered by Zoladex was actually decreasing it. Although 
the use of Zoladex was employed as an alternative to OVX 
for the induction of estrogen deﬁ  ciency, it was particularly 
interesting to note a very different response of the model 
to agonist treatment in terms of bone catabolism. Goulding 
and Gold (1989) had stated that “the degree of osteopenia 
elicited by OVX and buserelin treatment was similar” and 
that “administration of buserelin provides a new way of 
inducing estrogen-deﬁ  ciency osteopenia in the rat without 
removing the ovaries”. However, their own data do not really 
give credence to these statements. For example all the urine 
Hypro analyses for the agonist-treated rats gave lower values 
than the OVX group. In addition for half of the time points 
the urine Hypro concentration between controls and agonist 
treated animals were similar. What is also important to note 
is that although Goulding and Gold pitched their article 
advocating buserelin as a surrogate for OVX the authors 
postulate that the differences identiﬁ  ed for the two models 
may account for some steroidal protection in agonist treated 
rats. It is also possible that what Goulding and Gold had 
actually found was evidence of gonadotropins contributing to 
bone turnover but had overlooked their potential signiﬁ  cance. 
Similarly Tobias and colleagues (1994) noted key differ-
ences between OVX and buserelin treatment on indices of 
trabecular bone turnover in rats; whereas 90 days post OVX 
produced up to 80% tibial cancellous bone loss, buserelin 
resulted in approximately 40% loss. In addition parameters 
reﬂ  ecting changes in bone formation rate differed for the 
two models since buserelin treatment was not accompanied 
by increases in bone formation. Like Goulding and Gold, 
Tobias and colleagues suggested that the tool itself was to 
blame rather than providing a suggestion that gonadotropins 
in some way might be accountable. Importantly Yeh and col-
leagues (1996) subsequently revealed that an intact pituitary 
was necessary to trigger bone loss in response to estrogen 
withdrawal; whereas OVX resulted in marked bone loss, 
hypophysectomy in combination with OVX attenuated the 
osteopenic response. In light of the data that I had observed 
between Zoladex and OVX, I stated in my doctoral thesis 
that “These observations may support an important function 
for the gonadotropins in modulating the process of bone 
resorption.” These data have since been published (Mansell 
et al 2007), but for a few years after obtaining my PhD, bone 
biologists were reluctant to believe that gonadotropins had 
any role to play in skeletal metabolism following reports that 
LHRH agonists could cause osteopenia.
To further investigate the potential role of gonadotropins 
in skeletal development and morphology static histomor-
phometry and bone mineral density (BMD) were determined 
in mice nullizygous for the LH receptor (LuRKO) or mice 
overexpressing hCG. (Yarram et al 2003). Both groups 
exhibited skeletal phenotypes; male LuRKO mice had 
reduced bone mass for both femur and tibia whereas female 
hCG overexpressing mice had greatly elevated BMD at 
these sites. With regards to the latter model the circulating 
estrogen concentration was approximately double that of the 
wild type mice and would not have been sufﬁ  cient to cause 
the large increase (30%) in murine BMD given that only 
suprapharmacological levels of this steroid yield less than 
comparable BMD in mice (Samuels et al 1999). Importantly 
the increase in BMD reported for female hCG overexpressing 
mice could be prevented by OVX, thereby supporting a role 
of the ovary in generating the skeletal phenotype of these 
mice. One possible explanation however might be raised 
testosterone from hCG receptive thecal cells (Kumar 2005). 
Although the level of testosterone in the hCG overexpressing 
mice was elevated (∼6-fold) the potential for this steroid to 
explain the bone phenotype requires corroboration.
As stated above, the research gleaned from the application 
of LHRH agonists to treat prostate cancer and endometriosis 
has raised concerns regarding their impact on the skeleton. 
Importantly the research gathered from the use of these 
agonists indicates that gonadotropins do not participate in 
bone tissue metabolism. However, the magnitude of bone International Journal of General Medicine 2008:1 54
Mansell
loss appears to be small and “unlikely to be of any clinical 
relevance” (Fogelman 1992). Although there are studies 
identifying bone loss in response to LHRH agonist use 
there are also reports in which the risk of developing OP 
is no different to age-atched individuals in the community 
(eg, Peters et al 2001). Given that FSH/LH are greatly 
elevated at menopausal onset and that LHRH agonist admin-
istration does not mirror the skeletal changes observed for 
OVX it is possible that gonadotropins in some way contribute 
to bone catabolism.
Adrenal hyperplasia in response 
to LH: Could LH promote bone 
loss via cortisol upregulation?
A stark characteristic of the OVX rat/mouse is obesity; 
despite pair feeding with sham-operated controls, OVX 
animals always gain weight because of increases in intraab-
dominal fat. The increased fat and its distribution following 
OVX is likely linked to a Cushingoid state attributed to 
elevated glucocorticoids. Since the discovery of LH receptors 
in the adrenal gland and adrenal hyperfunction post OVX 
and the menopause (Kero et al 2000; Carlson 2007), it is 
tempting to hypothesize that raised LH post-OVX might 
drive bone catabolism via increased cortisol production. 
Excessive cortisol, as found for patients with Cushing’s 
syndrome, increases the risk of developing OP because 
glucocorticoids diminish bone-forming osteoblast numbers 
(Manolagas 2000; Mancini et al 2004).
Bone-resorbing osteoclasts 
are targets for FSH: the Mount 
Sinai Bone Program revelation
The perimenopausal period is associated with the most 
rapid phase of bone loss (Randolph et al 2004; Sowers 
et al 2006) even in the face of higher-than-premenopausal 
estrogen levels but very high circulating FSH (Prior 1998). 
Devleta and colleagues (2004) have recently provided a 
compelling association between raised FSH and osteopenia 
in ammenorrheic women. Similarly Kawai and colleagues 
(2004) correlate reduced FSH with bone accrual in response 
to estrogen. Collectively these ﬁ  ndings inspired the Mount 
Sinai Bone Program to investigate whether bone could be 
a target for FSH.
A combination of reverse transcription polymerase 
chain reaction (RT-PCR), ﬂ  ow cytometry, Western blot-
ting, and immunocytochemistry revealed that human and 
murine osteoclasts, and their precursors, expressed FSH 
receptors (FSHR). Osteoclastogenesis occurred when both 
human and murine bone marrow precursors were co-treated 
with FSH and receptor activator for nuclear factor kappa B 
(NF-κB)-ligand (RANK-L), a factor central for osteoclast 
formation. Furthermore FSH stimulated bone resorption and 
triggered phosphorylation of Erk, Akt, and Iκ-Bα, effectors 
of the proresorptive actions of RANK-L. There are now 
good data supporting the expression of Gi2α-coupled FSHR 
on osteoclasts and their precursors (Sun et al 2006).
In vivo, mice haploinsufﬁ  cient for FSHβ have raised 
bone mass precipitated by reduced osteoclast activity. Severe 
estrogen deﬁ  ciency occurs in response to FSHβ or FSHR 
ablation yet mice nullizygous for either have preserved 
bone mass despite being estrogen-deﬁ  cient. These striking 
ﬁ  ndings indicate that FSH directly participates in the regula-
tion of bone mass (Sun et al 2006; Zaidi et al 2007). Recall 
that a major local stimulus for driving bone resorption 
postmenopause is TNF-α and there are compelling studies 
putting TNF-α as a key mediator of bone loss in response to 
estrogen withdrawal (Paciﬁ  ci 1998, 2008); mice nullizygous 
for TNF-α do not lose bone in response to OVX (Roggia et al 
2001) and insensitivity to TNF-α protects against estrogen 
deﬁ  cient osteopaenia (Ammann et al 1997; Kimble et al 
1997; Charatcharoenwitthaya et al 2007). It is now known 
that this cytokine is mobilized by bone marrow precursors 
in response to FSH (Iqbal et al 2006).
The low-density lipoprotein 
receptor-related protein 5 (LRP5) 
gene is linked to circulating FSH 
in normal postmenopausal women
Low-density lipoprotein receptor-related protein 5 (LRP5) 
is a co-receptor for Wnt/β−catenin signalling (He et al 
2004). It is now known that LRP5 is required for osteoblast 
proliferation (Gong et al 2001; Kato et al 2002) and possibly 
the prevention of osteoblast apoptosis (Babij et al 2003). 
In a recent review of the literature (Mizuguchi et al 2004) 
it is becoming clear that LRP5/Wnt signaling is central for 
postnatal bone development and adult bone accrual making 
LRP5 an exciting candidate for further study in the context 
of musculoskeletal diseases, including osteoporosis and 
osteoarthritis.
Loss-of-function mutations in LRP5 result in osteoporo-
sis-pseudoglioma syndrome (OPPG), an autosomal recessive 
disorder (Gong et al 2001). Conversely a gain-in-function 
mutation, for example a G171V point mutation, results in 
elevated bone mass, enhanced alkaline phosphatase activity International Journal of General Medicine 2008:1 55
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and raised active osteoblast number (Babij et al 2003). 
Furthermore mutation analysis of families and patients 
has revealed at least 19 LRP5 sequence variants of which 
6 are thought to result in a high bone mass phenotype (Van 
Wesenbeeck et al 2003).
It has recently been reported that LRP5 is associated with 
circulating FSH in normal postmenopausal women (Zofkova 
et al 2007). A compelling association between serum FSH 
levels and a C/T (c.4037:A1330V) polymorphism in the 
LRP5 gene was identiﬁ  ed whereas no relationship was found 
for LH, estrogen testosterone or their precursors. The link 
between FSH and LRP5 strengthens the postulation that 
LRP5 is implicated in the changes accompanying the meno-
pause. In addition their relationship supports the concept of 
co-evolutionary mechanisms linking calcium homeostasis 
with reproductive biology.
Given the compelling association between the regulation 
of bone mass with LRP5 and the association between this 
co-receptor and circulating FSH, the dynamic relation-
ship between LRP5 and FSH certainly warrants closer 
investigation into bone metabolism postmenopause.
Concluding remarks
The revelation made by Sun and colleagues (2006) that FSH 
is the chief miscreant for postmenopausal OP has sparked 
considerable debate amongst leading researchers in the ﬁ  eld 
(Baron 2006; Martin and Gaddy 2006; Seibel et al 2006; 
Prior 2007); Seibel and colleagues (2006) postulate that the 
osteopaenic resistance in FSHR/ FSHβ nullizygous mice is 
attributed to raised testosterone in the face of elevated LH. 
Furthermore there are no reports of lower rates of bone loss 
for individuals with pituitary insufﬁ  ciency compared to those 
with raised gonadotropins in response to natural or surgical 
menopause. In this regard Seibel and colleagues suggest that 
differences in the levels of sex steroids explain the skeletal 
phenotype reported by Sun and colleagues (2006). However 
it is important to recognize those clinical and natural endo-
crine events in which the estrogen-deﬁ  ciency-osteoporosis 
model does not hold; importantly the rate of bone loss is 
greater during the perimenopause than during the ﬁ  rst years 
postmenopause when estrogen levels are lower. Also, both 
estrogen and progesterone are required to negate premeno-
pausal bone losses. Whilst Jerilynn Prior (2007) acknowl-
edges that the estrogen-deﬁ  ciency-osteoporosis model “faces 
considerable challenge” all are in agreement that much more 
research into the potential role of gonadotropins in skeletal 
physiology will have to be undertaken to displace it. Although 
we are far from a paradigm shift it is highly likely that our 
understanding of the skeletal response to estrogen deﬁ  ciency 
will widen and with it changes in our approach to treating 
and preventing postmenopausal OP.
Acknowledgments
The author is indebted to Dr Alice May Roberts, University 
of Bristol, for the artwork presented in this review. 
The authors report no conﬂ  icts of interest in this work.
References
Albright F, Smith PH, Richardson AM. 1941. Postmenopausal osteoporosis-its 
clinical features. JAMA, 116:2465–74.
Ammann P, Rizzoli R, Bonjour JP, et al. 1997. Transgenic mice expressing 
soluble tumor necrosis factor-receptor are protected against bone loss 
caused by estrogen deﬁ  ciency. J Clin Invest, 99:1699–703.
Babij P, Zhao W, Small C, et al. 2003. High bone mass in mice expressing 










Figure 1 A summary of how follicle stimulating hormone (FSH) and luteinizing 
hormone (LH) might co-operate in promoting bone catabolism postmenopause. 
Elevated levels of LH are known to induce adrenal cortex hyperfunction and resultant 
increases in circulating cortisol. It is postulated that increased cortisol in response 
to raised LH postmenopause impacts upon bone forming osteoblasts by inhibiting 
bone matrix synthesis through dampening osteoblast activity. In the long term the 
effect of raised cortisol will contribute to osteopaenia and the subsequent develop-
ment of osteoporosis. Increasing levels of FSH could target at least two different 
compartments of bone tissue; the bone resorbing osteoclast population and bone 
marrow macrophage precursors. With regard to the former, FSH has been shown 
to directly activate osteoclastic resorption. With reference to the bone marrow, 
resident macrophage precursors are now known to mobilise tumor necrosis factor 
alpha (TNF-α) in response to FSH. TNF-α is a key player in the demise of bone 
postmenopause through stimulating osteoclastic bone resorption. In this model 
elevated LH and FSH co-operate in fuelling net bone loss thereby increasing the 
risk of developing osteoporosis.International Journal of General Medicine 2008:1 56
Mansell
Bain SD, Bailey MC, Celino DL, et al. 1993. High-dose estrogen inhibits 
bone resorption and stimulates bone formation in the ovariectomized 
mouse. J Bone Miner Res, 8:435–42.
Baron R. 2006. FSH versus estrogen: who’s guilty of breaking bones? Cell 
Metab, 3:302–5.
Carlson HE. 2007. Human adrenal cortex hyperfunction due to LH/hCG. 
Mol Cell Endocrinol, 269:46–50.
Charatcharoenwitthaya N, Khosla S, Atkinsn EJ, et al. 2007. Effect of 
blockade of tumor necrosis factor-alpha and interleukin-1 action on 
bone resorption in early postmenopausal women. J Bone Miner Res, 
22:724–9.
Devleta B, Adem B, Senada S. 2004. Hypergonadotropic amenorrhea and 
bone density: new approach to an old problem. J Bone Miner Res, 
22:360–4.
Eriksen EF, Colward DS, Bery NJ, et al. 1988. Evidence of oestrogen 
receptors in normal human osteoblast-like cells. Science, 241:84.
Ernst M, Health JK, Rodan GA. 1989. Estradiol effects on proliferation, 
messenger ribonucleic acid for collagen and insulin-like growth 
factor I, and parathyroid hormone-stimulated adenylate cyclase activity 
in osteoblastic cells from calvariae and long bones. Endocrinology, 
125:825–33.
Fogelman MD. 1992. Gonadotropin-releasing hormone agonists and the 
skeleton. Fertil Steril, 57:715–24.
Gong Y, Slee RB, Fukai N, et al. 2001. LDL receptor-related protein 5 (LRP5) 
affects bone accrual and eye development. Cell, 107:513–23.
Goulding A, Gold E. 1989. A new way to induce oestrogen deﬁ  cient 
osteopaenia in the rat: comparison of the effects of surgical ovariectomy 
and administration of the LHRH agonist buserelin on bone resorption 
and composition. J Endocrinol, 121:293–8.
Gray TK. 1989. Oestrogens and the skeleton: cellular and molecular 
mechanisms. J Steroid Biochem, 34:285–7.
He X, Semenov M, Tamai K, et al. 2004. LDL receptor related protein 5 and 
6 in Wnt/beta-catenin signalling: arrows point the way. Development, 
131:1663–77.
Iqbal JL, Sun L, Kumar TR, et al. 2006. Follicle stimulating hormone 
stimulates TNF production from immune cells to enhance osteoblast 
and osteoclast formation. Proc Natl Acad Sci U S A, 103:14925–30.
Kato M, Patel MS, Levasseur R, et al. 2002. Cbfa-1 independent decrease 
in osteoblast proliferation,osteopaenia, and persistent embryonic eye 
vascularisation in mice deﬁ  cient in LRP5, a Wnt coreceptor. J Cell 
Biol, 157:303–14.
Kawai H, Furuhashi M, Suganuma N. 2004. serum follicle stimulating 
hormone level is a predictor of bone mineral density in patients with 
hormone replacement therapy. Arch Gynecol Obstet, 269:192–5.
Keeting PE, Scott RE, Colward DS, et al. 1991. Lack of a direct effect 
of oestrogen on proliferation and differentiation of normal human 
osteoblast-like cells. J Bone Miner Res, 6:297–304.
Kero J, Poutanen M, Zhang F-P, et al. 2000. Elevated luteinizing hormone 
induces expression of its receptor and promotes steroidogenesis in the 
adrenal cortex. J Clin Invest, 105:633–41.
Kimble R, Bain S, Paciﬁ  ci R. 1997. The functional block of TNF but nor 
of IL-6 prevents bone loss in ovariectomized mice. J Bone Miner Res, 
12:935–41.
Komm BS, Terpening CM, Binz DJ, et al. 1988. Estrogen binding, receptor 
mRNA and biologic response in osteoblast-like osteosarcoma cells. 
Science, 241:81–4.
Kumar TR. 2005. What have we learned about gonadotropin function from 
gonadotropin subunit and receptor knockout mice? Reproduction, 
130:293–302.
Lindberg MK, Alatalo SL, Halleen JM, et al. 2001. Estrogen receptor 
speciﬁ  city in the regulation of the skeleton in female mice. J Endocrinol, 
171:229–36.
Lindsay R. 2004. Hormones and bone health in postmenopausal women. 
Endocrine, 24:223–30.
Mahonen A, Jukkola A, Risteli L, et al. 1998. Type I procollagen synthesis 
is regulated by steroids and related hormones in human osteosarcoma 
cells. J Cell Biochem, 68:151–63.
Mancini T, Doga M, Mazziotti G, et al. 2004. Cushing’s syndrome and 
bone. Pituitary, 7:243–6.
Manolagas SC. 2000. Birth and death of bone cells: basic regulatory 
mechanisms and implications for the pathogenesis and treatment of 
osteoporosis. Endocr Rev, 21:115–37.
Mansell JP, Bailey AJ, Yarram SJ. 2007. Could bone tissue be a target for 
luteinizing hormone/chorionic gonadotropin? Mol Cell Endocrinol, 
269:99–106.
Martin JT, Gaddy D. 2006. Bone loss goes beyond estrogen. Nature Med, 
12:612–3.
McCauley LK, Tözüm TF, Rosol TJ. 2002. Estrogen receptors in skeletal 
metabolism: lessons from genetically modiﬁ  ed models of receptor 
function. Crit Rev Eukaryot Gene Expr, 12:89–100.
McOsker JE, Li XJ. 1991. Use of rectilinear single photon absorptiometry to 
evaluate bone mass changes in rats. Scanning Microscopy International, 
Chicago. Cell Mater Suppl 1:93–104.
Medvei VC. 1982. A history of endocrinology. Norwell, MA: Kluwer 
Academic Publishers.
Mizuguchi T, Furuta I, Watanabe Y, et al. 2004. LRP5, low density-
lipoprotein-receptor-related protein 5, is a determinant for bone mineral 
density. J Hum Genet, 49:80–6.
Nakamura T, Imai Y, Matsumoto T, et al. 2007. Estrogen prevents bone loss 
via estrogen receptor alpha and induction of Fas ligand in osteoclasts. 
Cell, 130:811–23.
Pacifici R. 1998. Editorial: cytokines, estrogen, and postmenopausal 
osteoporosis – the second decade. Endocrinology, 139:2659–61.
Paciﬁ  ci R. 2000. Estrogen deﬁ  ciency, T cells and bone loss. Cell Immunol, 
252(1–2):68–80.
Peters JL, Fairney A, Kyd P, et al. 2001. Bone loss associated with the 
use of LHRH agonists in prostate cancer. Prostate Cancer Prostatic 
Dis, 4:161–6.
Prior JC. 1998. Perimenopause: the complex endocrinology of the 
menopausal transition. Endocrinol Rev, 19:397–428.
Prior JC. 2007. FSH and bone-important physiology or not? Trends Mol 
Med, 13:1–3.
Randolph JF, Sowers M, Bondarenko IV , et al. 2004. Change in estradiol 
and follicle stimulating hormone across the early menopausal transition: 
effects of ethnicity and age. J Clin Endocrinol Metab, 89:1555–61.
Robinson JA, Harris SA, Riggs BL, et al. 1997. Estrogen regulation of 
human osteoblastic cell proliferation and differentiation. Endocrinology, 
138:2919–27.
Rodan GA. 1991. Mechanical loading, oestrogen deficiency, and the 
coupling of bone formation to bone resorption. J Bone Miner Res, 
6:527–9.
Roggia C, Gao Y, Genci S, et al. 2001. Up-regulation of TNF-producing 
T cells in the bone marrow: a key mechanism by which estrogen 
deﬁ  ciency induces bone loss in vivo. Proc Natl Acad Sci U S A, 
98:13960–5.
Samuels A, Perry MJ, Tobias JH. 1999. High-dose estrogen induces de 
novo medullary bone formation in female mice. J Bone Miner Res, 
14:178–86.
Saville PD. 1969. Changes in skeletal mass and fragility with castration in 
the rat: a model of osteoporosis. J Am Geriatrics Soc, 17:155–64.
Seibel MJ, Dunstan CR, Zhou H, et al. 2006. Sex steroids, not FSH, inﬂ  uence 
bone mass. Cell, 127:1079.
Sowers MR, Jannausch M, McConnell D, et al. 2006. Hormone predictors of 
bone mineral density changes during the menopausal transition. J Clin 
Endocrinol Metab, 91:1261–7.
Stevenson JC. 2005. Justiﬁ  cation for the use of HRT in the long-term 
prevention of osteoporosis. Maturitas, 51:113–26.
Sun L, Peng Y, Sharrow AC, et al. 2006. FSH directly regulates bone mass. 
Cell, 125:247–60.
Tobias JH, Chambers TJ, Gallagher A. 1994. Effect of administration and 
subsequent cessation of buserelin on cancellous bone of female rats. 
J Bone Miner Res, 9:1919–25.
Turner RT, Riggs BL, Spelsberg TC. 1994. Skeletal effects of estrogen. 
Endocrinol Rev, 15:275–300.International Journal of General Medicine 2008:1 57
Gonadotropins and the skeleton
Turner RT. 1999. Mice, estrogen, and postmenopausal osteoporosis. J Bone 
Miner Res, 14:187–91.
Van Wesenbeeck L, Cleiren E, Gram J, et al. 2003. Six novel missense 
mutations in the LDL receptor-related protein 5 (LRP5) gene in 
different conditions with an increased bone density. Am J Hum Genet, 
72:763–71.
Ward JA, Furr BJ, Valcaccia B, et al. 1989. Prolonged suppression of rat 
testis function by a depot formulation of Zoladex, a GnRH agonist. 
J Androl, 10:478–86.
Westerlind KC, Wakley GK, Evans GL, et al. 1993. Estrogen does 
not increase bone formation in growing rats. Endocrinology, 
133:2924–34.
Windahl SH, Andersson G, Gustafsson JA. 2002. Elucidation of estrogen 
receptor function in bone with the use of mouse models. Trends 
Endocrinol Metab, 13:195–200.
Wronski TJ, Yen CF. 1991. The ovariectomised rat as an animal model 
for postmenopausal bone loss. Scanning Microscopy International, 
Chicago. Cells Mater Suppl, 1:69–74.
Yarram SJ, Perry MJ, Christopher TJ, et al. 2003. Luteinizing hormone 
receptor knockout (LuRKO) mice and transgenic human chorionic 
gonadotropin (hCG) overexpressing mice (hCGαβ+) have bone 
phenotypes. Endocrinology, 144:3555–64.
Yeh JK, Chen MM, Aloia JF. 1996. Ovariectomy-induced high turnover 
in cortical bone is dependent on pituitary hormone in rats. Bone, 
18:443–50.
Zaidi M, Blair HC, Iqbal J, et al. 2007. Proresorptive actions of FSH and 
bone loss. Ann NY Acad Sci, 1116:376–82.
Zofkova I, Hill M, Zajickova K. 2007. Association of C/T polymorphism 
in the LRP5 gene with circulating follicle stimulating hormone in 
Caucasian postmenopausal women. Physiol Res, 56:735–9.